Home LiteratureArticle Details
PMID: 776493 Published · ppublish English Clinical Trial Journal Article

Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations.

Clinical radiology ·Vol. 27 ·No. 2 ·1976-04-00 ·Pages 151-7

Gray AJ, Dische S, Adams GE, Flockhart IR, Foster JL

Abstract

Patients have been given single oral doses of the radiosensitiser Ro-07-0582 and serum concentrations have been attained in the range expected to be of value in radiosensitisation. Immediate gastrointestinal side effects appear to limit the dose to below 140 mg/kg but radiosensitising serum levels of approximately 200 mug/ml can be attained. Tolerance may be improved by giving anti-emetics and a more palatable preparation. Estimates of the concentration of Ro-07-0582 in tumour have ranged from 12 to 92% of the serum concentration at the time of determination.

MeSH Terms
Adult Aged Biopsy Breast Neoplasms/radiotherapy Carcinoma/analysis,radiotherapy Clinical Trials as Topic Humans Middle Aged Nausea/etiology Neoplasm Metastasis Nervous System Diseases/etiology Neurologic Examination Nitroimidazoles/adverse effects,analysis,blood Radiation-Sensitizing Agents/adverse effects Radiography Sarcoma/analysis,radiotherapy Skull/diagnostic imaging Taste Vomiting/etiology
Chemicals
Nitroimidazoles Radiation-Sensitizing Agents
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Gray A J
Dische S
Adams G E
Flockhart I R
Foster J L
Article Info
Journal
Clinical radiology
Abbr.
Clin Radiol
ISSN
0009-9260
Published
1976-04-00
Pages
151-7
Language
English
Region
England
NLM ID
1306016
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]